Lakefront Biotherapeutics NV (LKFT)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from LKFT's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from Lakefront Biotherapeutics NV's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $234M | $241M | $240M | $276M | $1.1B |
| Net income | -$103M | -$218M | $212M | $74M | $321M |
| Free cash flow | -$562M | -$537M | -$425M | -$402M | -$271M |
| EPS (diluted) | -$1.58 | -$3.32 | $3.21 | $1.12 | $4.87 |
| Operating margin | -73.2% | -54.3% | -36.8% | -68.3% | 26.5% |
Where the revenue comes from
Revenue by segments, fiscal 2019. Every breakdown, year by year.
Superinvestors who own LKFT
From each investor's latest 13F filing (what a 13F shows).
Insider buying
Open-market purchases by Lakefront Biotherapeutics NV's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when LKFT trades at or below it.
New accounts get 7 days of Pro, price alerts included. No card needed.
In the full deep dive
Questions
Are Lakefront Biotherapeutics NV insiders buying the stock?
No open-market insider purchases of LKFT in the last 12 months, according to SEC Form 4 filings.
Companies like Lakefront Biotherapeutics NV
All Healthcare stocks · Biotechnology stocks · Stock lists
Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.